MTAP deletion
|
Solid Tumor
|
MTAP deletion
|
Solid Tumor
|
TNG908 Sensitive: C2 – Inclusion Criteria
|
TNG908 Sensitive: C2 – Inclusion Criteria
|
MTAP deletion
|
Urothelial Cancer
|
MTAP deletion
|
Urothelial Cancer
|
pemetrexed Sensitive: C3 – Early Trials
|
pemetrexed Sensitive: C3 – Early Trials
|
MTAP deletion
|
LUAD
|
MTAP deletion
|
LUAD
|
pemetrexed Sensitive: C3 – Early Trials
|
pemetrexed Sensitive: C3 – Early Trials
|
MTAP deletion
|
SCCHN
|
MTAP deletion
|
SCCHN
|
pembrolizumab + afatinib Resistant: C3 – Early Trials
|
pembrolizumab + afatinib Resistant: C3 – Early Trials
|
MTAP deletion
|
Gastric Cancer
|
MTAP deletion
|
Gastric Cancer
|
IDE397 Sensitive: D – Preclinical
|
IDE397 Sensitive: D – Preclinical
|
MTAP deletion
|
Esophageal Cancer
|
MTAP deletion
|
Esophageal Cancer
|
IDE397 Sensitive: D – Preclinical
|
IDE397 Sensitive: D – Preclinical
|
MTAP deletion
|
Head and Neck Cancer
|
MTAP deletion
|
Head and Neck Cancer
|
IDE397 Sensitive: D – Preclinical
|
IDE397 Sensitive: D – Preclinical
|
MTAP deletion
|
Pancreatic Cancer
|
MTAP deletion
|
Pancreatic Cancer
|
IDE397 Sensitive: D – Preclinical
|
IDE397 Sensitive: D – Preclinical
|
MTAP deletion
|
Bladder Cancer
|
MTAP deletion
|
Bladder Cancer
|
IDE397 Sensitive: D – Preclinical
|
IDE397 Sensitive: D – Preclinical
|
MTAP deletion
|
NSCLC
|
MTAP deletion
|
NSCLC
|
IDE397 Sensitive: D – Preclinical
|
IDE397 Sensitive: D – Preclinical
|
MTAP deletion
|
CRC
|
MTAP deletion
|
CRC
|
MRTX9768 Sensitive: D – Preclinical
|
MRTX9768 Sensitive: D – Preclinical
|